Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis

Company Overview

Ampio Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing therapies that modulate the body’s inflammatory response to alleviate pain and improve functional outcomes. Headquartered in Englewood, Colorado, the company leverages proprietary plasma‐derived and synthetic formulations to target chronic musculoskeletal and cardiovascular conditions.

The company’s lead product candidate, Ampion, is a novel, low‐molecular‐weight fraction of human serum albumin designed as a single intra‐articular injection for patients suffering from osteoarthritis of the knee. Ampio is also advancing an intravenous formulation of this inflammation‐modulating technology for the treatment of acute cardiovascular injury and ischemia‐reperfusion damage. These programs are supported by preclinical studies and early‐stage clinical data demonstrating reduced inflammatory markers and improved tissue recovery.

Since its inception, Ampio has built a development‐stage portfolio under the leadership of President and Chief Executive Officer Mark A. Biancamano. The company’s management team combines expertise in biologics manufacturing, clinical trial operations and regulatory affairs. Ampio maintains partnerships with contract research organizations and specialized manufacturing sites to support its pipeline advancement.

Ampio Pharmaceuticals conducts its research and clinical activities primarily in the United States, collaborating with academic centers, clinical investigators and regulatory consultants. The company continues to pursue U.S. Food and Drug Administration guidance as it aims to transition its lead candidates from clinical development toward potential commercialization.

Key Stats

• Today's Range: $0.0052 to $0.0052
• 50-Day Range: $0.01 to $0.29
• 52-Week Range: $0.00 to $0.30
• Volume: 11 shs
• Average Volume: 2,474 shs
• Market Capitalization: $5.90 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMPE Stock Analysis - Frequently Asked Questions

How have AMPE shares performed this year?

Ampio Pharmaceuticals' stock was trading at $0.0052 at the start of the year. Since then, AMPE shares have increased by 0.0% and is now trading at $0.0052.

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.40).

When did Ampio Pharmaceuticals' stock split?

Ampio Pharmaceuticals's stock reverse split on the morning of Tuesday, September 12th 2023.The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ampio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:AMPE
• CIK: 1411906
• Web: ampiopharma.com
• Phone: 720-437-6500
• Fax: 720-437-6501
• Employees: 20
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,135,000
• Free Float: 1,098,000
• Market Cap: $5.90 thousand
• Optionable: No Data
• Beta: 7.65